Literature DB >> 32485148

ERK2 Phosphorylates PFAS to Mediate Posttranslational Control of De Novo Purine Synthesis.

Eunus S Ali1, Umakant Sahu1, Elodie Villa1, Brendan P O'Hara1, Peng Gao2, Cynthia Beaudet3, Antony W Wood3, John M Asara4, Issam Ben-Sahra5.   

Abstract

The RAS-ERK/MAPK (RAS-extracellular signal-regulated kinase/mitogen-activated protein kinase) pathway integrates growth-promoting signals to stimulate cell growth and proliferation, at least in part, through alterations in metabolic gene expression. However, examples of direct and rapid regulation of the metabolic pathways by the RAS-ERK pathway remain elusive. We find that physiological and oncogenic ERK signaling activation leads to acute metabolic flux stimulation through the de novo purine synthesis pathway, thereby increasing building block availability for RNA and DNA synthesis, which is required for cell growth and proliferation. We demonstrate that ERK2, but not ERK1, phosphorylates the purine synthesis enzyme PFAS (phosphoribosylformylglycinamidine synthase) at T619 in cells to stimulate de novo purine synthesis. The expression of nonphosphorylatable PFAS (T619A) decreases purine synthesis, RAS-dependent cancer cell-colony formation, and tumor growth. Thus, ERK2-mediated PFAS phosphorylation facilitates the increase in nucleic acid synthesis required for anabolic cell growth and proliferation.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ERK; FGAM; MAPK; PFAS; RAS; cancer; nucleotide synthesis; posttranslational modification; purine metabolism; tumor growth

Mesh:

Substances:

Year:  2020        PMID: 32485148      PMCID: PMC7306006          DOI: 10.1016/j.molcel.2020.05.001

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  65 in total

1.  Regulation of c-myc expression by Ras/Raf signalling.

Authors:  E Kerkhoff; R Houben; S Löffler; J Troppmair; J E Lee; U R Rapp
Journal:  Oncogene       Date:  1998-01-15       Impact factor: 9.867

Review 2.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation.

Authors:  Michelle C Mendoza; E Emrah Er; John Blenis
Journal:  Trends Biochem Sci       Date:  2011-04-30       Impact factor: 13.807

3.  A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

Authors:  György Bodoky; Constanta Timcheva; David Robert Spigel; Phillip Joseph La Stella; Tudor Eliade Ciuleanu; G Pover; N C Tebbutt
Journal:  Invest New Drugs       Date:  2011-05-19       Impact factor: 3.850

Review 4.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells.

Authors:  Wei Zhang; Hui Tu Liu
Journal:  Cell Res       Date:  2002-03       Impact factor: 25.617

5.  Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer.

Authors:  Timothy J Humpton; Brinda Alagesan; Gina M DeNicola; Dan Lu; Georgi N Yordanov; Carl S Leonhardt; Melissa A Yao; Priya Alagesan; Maya N Zaatari; Youngkyu Park; Jeremy N Skepper; Kay F Macleod; Pedro A Perez-Mancera; Michael P Murphy; Gerard I Evan; Karen H Vousden; David A Tuveson
Journal:  Cancer Discov       Date:  2019-07-01       Impact factor: 39.397

Review 6.  MYC, Metabolism, and Cancer.

Authors:  Zachary E Stine; Zandra E Walton; Brian J Altman; Annie L Hsieh; Chi V Dang
Journal:  Cancer Discov       Date:  2015-09-17       Impact factor: 39.397

Review 7.  Transcriptional regulation by MAP kinases.

Authors:  R J Davis
Journal:  Mol Reprod Dev       Date:  1995-12       Impact factor: 2.609

Review 8.  Metabolic dysregulation in monogenic disorders and cancer - finding method in madness.

Authors:  Ayelet Erez; Ralph J DeBerardinis
Journal:  Nat Rev Cancer       Date:  2015-06-18       Impact factor: 69.800

Review 9.  Regulation of mammalian nucleotide metabolism and biosynthesis.

Authors:  Andrew N Lane; Teresa W-M Fan
Journal:  Nucleic Acids Res       Date:  2015-01-27       Impact factor: 16.971

10.  Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway.

Authors:  L J Bugaj; A J Sabnis; A Mitchell; J E Garbarino; J E Toettcher; T G Bivona; W A Lim
Journal:  Science       Date:  2018-08-31       Impact factor: 47.728

View more
  14 in total

1.  The mTORC1-SLC4A7 axis stimulates bicarbonate import to enhance de novo nucleotide synthesis.

Authors:  Eunus S Ali; Anna Lipońska; Brendan P O'Hara; David R Amici; Michael D Torno; Peng Gao; John M Asara; Mee-Ngan F Yap; Marc L Mendillo; Issam Ben-Sahra
Journal:  Mol Cell       Date:  2022-06-29       Impact factor: 19.328

2.  Clinical Targeting of Altered Metabolism in High-Grade Glioma.

Authors:  Andrew J Scott; Costas A Lyssiotis; Daniel R Wahl
Journal:  Cancer J       Date:  2021 Sep-Oct 01       Impact factor: 3.360

Review 3.  The Purinosome: A Case Study for a Mammalian Metabolon.

Authors:  Anthony M Pedley; Vidhi Pareek; Stephen J Benkovic
Journal:  Annu Rev Biochem       Date:  2022-03-23       Impact factor: 27.258

4.  SChLAP1 promotes prostate cancer development through interacting with EZH2 to mediate promoter methylation modification of multiple miRNAs of chromosome 5 with a DNMT3a-feedback loop.

Authors:  Kai Huang; Yuxin Tang
Journal:  Cell Death Dis       Date:  2021-02-15       Impact factor: 8.469

5.  Methionine oxidation of CLK4 promotes the metabolic switch and redox homeostasis in esophageal carcinoma via inhibiting MITF selective autophagy.

Authors:  Yaxing Shen; Heng Zhang; Shihua Yao; Feng Su; Hao Wang; Jun Yin; Yong Fang; Lijie Tan; Kaiguang Zhang; Xiangshan Fan; Ming Zhong; Qingxin Zhou; Jie He; Zhiyong Zhang
Journal:  Clin Transl Med       Date:  2022-01

6.  Uric acid accumulation in DNA-damaged tumor cells induces NKG2D ligand expression and antitumor immunity by activating TGF-β-activated kinase 1.

Authors:  Jingxiang Wang; Kai Liu; Tianxiang Xiao; Penggang Liu; Richard A Prinz; Xiulong Xu
Journal:  Oncoimmunology       Date:  2022-01-02       Impact factor: 8.110

Review 7.  Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response.

Authors:  Yarden Ariav; James H Ch'ng; Heather R Christofk; Noga Ron-Harel; Ayelet Erez
Journal:  Sci Adv       Date:  2021-05-19       Impact factor: 14.136

Review 8.  Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment.

Authors:  Samuel A Kerk; Thales Papagiannakopoulos; Yatrik M Shah; Costas A Lyssiotis
Journal:  Nat Rev Cancer       Date:  2021-07-09       Impact factor: 69.800

Review 9.  Human de novo purine biosynthesis.

Authors:  Vidhi Pareek; Anthony M Pedley; Stephen J Benkovic
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-11-12       Impact factor: 8.250

Review 10.  Cancer metabolism: looking forward.

Authors:  Inmaculada Martínez-Reyes; Navdeep S Chandel
Journal:  Nat Rev Cancer       Date:  2021-07-16       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.